Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY23 results · Jan–Mar 2023
Eris Lifesciences reported revenue from operations of ₹402.80 crore (up 31.7% from Q4 FY22) and net profit of ₹61.48 crore (down 23.1% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 402.80 | 305.95 | +31.7% | 423.26 | −4.8% |
| Other income | 1.00 | 8.06 | −87.5% | 2.24 | −55.1% |
| Total income | 403.80 | 314.01 | +28.6% | 425.50 | −5.1% |
| Profit before tax | 75.90 | 85.34 | −11.1% | 106.54 | −28.8% |
| Net profit for the period | 61.48 | 79.97 | −23.1% | 100.23 | −38.7% |
| Attributable to shareholders of the company | 65.42 | 80.30 | −18.5% | 101.86 | −35.8% |
| EPS, basic (₹) | 4.81 | 5.91 | −18.6% | 7.49 | −35.8% |
| Net margin (%) | 15.3 | 26.1 | 23.7 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 314.58 | 282.14 | +11.5% | 332.01 | −5.2% |
| Other income | 4.26 | 9.05 | −52.9% | 3.48 | +22.4% |
| Total income | 318.84 | 291.19 | +9.5% | 335.49 | −5.0% |
| Profit before tax | 95.51 | 94.63 | +0.9% | 110.23 | −13.4% |
| Net profit for the period | 87.84 | 86.71 | +1.3% | 99.38 | −11.6% |
| EPS, basic (₹) | 6.46 | 6.38 | +1.3% | 7.31 | −11.6% |
| Net margin (%) | 27.9 | 30.7 | 29.9 |
Consolidated
- Filed with BSE
- 26 May 2023, 11:25 IST
- Board meeting
- 17 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2023, 11:25 IST
- Board meeting
- 17 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE